ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

ASLAN Pharmaceuticals Limited

No. 12-03 UE Square
83 Clemenceau Avenue
Singapore 239920
Singapore
65 6222 4235
http://www.aslanpharma.com

SectorHealthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Carl Alan Jason Morton FirthChairman & CEON/AN/A1973
Mr. Kiran AsarpotaVP of Fin.N/AN/AN/A
Dr. Mark McHaleChief Operating OfficerN/AN/AN/A
Charlie HsuInvestor Relations DirectorN/AN/AN/A
Mr. Ben GoodgerGen. CounselN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors. It is also developing ASLAN004, a monoclonal IL4/IL13 antibody that is under preclinical development for asthma and other tumor types; and ASLAN005, a monoclonal antibody, which is under preclinical development for RON, an immune checkpoint inhibitor. In addition, the company is also discovering Modybodies that are a novel type of antibody fragments, which can be linked together into heterodimers/trimers to inhibit various targets. ASLAN Pharmaceuticals Limited was founded in 2014 and is headquartered in Singapore.

Corporate governance

ASLAN Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.